Regencell Bioscience Holdings, a Hong Kong biotech focused on Traditional Chinese Medicine for neurocognitive disorders, experienced an extraordinary stock price surge of up to 82,000% YTD in 2025, fueled by a 38-for-1 stock split and speculative retail frenzy rather than product or regulatory milestones. Despite no approved products or revenue, the stock briefly reached $83.60 before crashing 74%, stabilizing around $17 by October. Regulatory trading halts addressed extreme volatility. Analysts liken the event to meme-stock phenomena with heavy short squeezing.